As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term phase 2 data for its bowel disease bet as showing the Teva-partnered prospect remains a “key opportunity in our pipeline.”
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
As Sanofi attempts to bounce back from a tough year of clinical readouts, the French pharma has touted longer-term phase 2 data for its bowel disease bet as showing the Teva-partnered prospect remains a “key opportunity in our pipeline.”